ArticleThe oncologist2012
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Article in The oncologist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis.Journal of pharmaceutical analysis · 2024Article
- METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.BMC gastroenterology · 2023Article
- Design, synthesis, and cytotoxic activities of isaindigotone derivatives as potential anti-gastric cancer agents.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- Stromal CD10 expression in gastric adenocarcinoma.Journal of medicine and life · 2022Article
- A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.BMC cancer · 2021Article
- Expression of Human epidermal growth factor receptor 2, Survivin, Enhancer of zeste homolog -2, Cyclooxygenase-2, p53 and p16 molecular markers in Gall bladder carcinoma.Journal of carcinogenesis · 2021Article
- Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery.Gastroenterology research and practice · 2019Article
- The function of Notch1 intracellular domain in the differentiation of gastric cancer.Oncology letters · 2018Article
- Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer.Oncology letters · 2018Article
- High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.British journal of cancer · 2017Article
- Anti-metastatic activity of fangchinoline in human gastric cancer AGS cells.Oncology letters · 2017Article
- Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.OncoTargets and therapy · 2017Article
- Advances of Molecular Targeted Therapy in Gastric Cancer.Journal of gastrointestinal cancer · 2016Review
- Effects of ophiopogonin B on the proliferation and apoptosis of SGC‑7901 human gastric cancer cells.Molecular medicine reports · 2016Article
- URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro.American journal of cancer research · 2016Article
- Targeted therapy for advanced gastric cancer: A review of current status and future prospects.World journal of gastrointestinal oncology · 2015Review
- HER2/neu-directed therapy for biliary tract cancer.Journal of hematology & oncology · 2015Article
- WAVE3 promotes epithelial-mesenchymal transition of gastric cancer through upregulation of Snail.Cancer gene therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is one of the leading causes of cancer death. With greater understanding of the molecular basis of carcinogenesis, targeted agents have led to a modest improvement in the outcome of advanced gastric cancer (AGC) patients. METHODS AND
resultsWe conducted an overview of the published evidence regarding the use of targeted therapy in AGC patients. Thus far, the human epidermal growth factor receptor (HER) pathway, angiogenic pathway, and phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of rapamycin pathway have emerged as potential avenues for targeted therapy in AGC patients. The promising efficacy results of the Trastuzumab for Gastric Cancer trial led to the approved use of trastuzumab-based therapy as first-line treatment for patients with HER-2+ AGC. On the other hand, the Avastin® in Gastric Cancer trial evaluating bevacizumab in combination with chemotherapy did not meet its primary endpoint of a longer overall survival duration despite a significantly higher response rate and longer progression-free survival time in patients in the bevacizumab arm. Phase III data are awaited for other targeted agents, including cetuximab, panitumumab, lapatinib, and everolimus.
conclusionRecent progress in targeted therapy development for AGC has been modest. Further improvement in the outcome of AGC patients will depend on the identification of biomarkers in different patient populations to facilitate the understanding of gastric carcinogenesis, combining different targeted agents with chemotherapy, and unraveling new molecular targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.